- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON 03.07.2026 | 69 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.07.2026
Aktien
1 JP3100020001 Archion Corp.
2 US73110F1003... ► Artikel lesen | |
| 28.05. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Polaryx Therapeutics sichert sich 10 Millionen US-Dollar über PIPE-Finanzierung | 1 | Investing.com Deutsch | ||
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial | 1 | GlobeNewswire (USA) | ||
| 14.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards | 4 | GlobeNewswire (USA) | ||
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 272 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 283 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 12.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events | 2 | GlobeNewswire (USA) | ||
| 27.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | 1 | GlobeNewswire (USA) | ||
| 17.02. | Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans | 1 | Benzinga.com | ||
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 912 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 05.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Welcomes New Members of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 02.02. | Micro-cap Polaryx Therapeutics to trade on the Nasdaq today via direct listing | 2 | Renaissance Capital | ||
| 02.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" | 353 | GlobeNewswire (Europe) | PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 30.01. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq | 292 | GlobeNewswire (Europe) | PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 27.01. | Polaryx Therapeutics, Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 27.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,480 | -0,47 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,590 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,320 | -0,45 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,354 | +4,12 % | NurExone-Tochter Exo-Top ebnet Weg in den mexikanischen Exosomenmarkt | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,518 | +3,58 % | Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why | ||
| REDHILL BIOPHARMA | 0,815 | +0,34 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| ONCO-INNOVATIONS | 0,442 | -1,34 % | Onco-Innovations leitet Studien zur Verstoffwechselung von ONC010 in Hepatozyten und Lebermikrosomen aus drei Tierarten ein | Vancouver, Kanada - 26. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") kündigt die Einleitung von Studien... ► Artikel lesen | |
| NOVOCURE | 14,915 | -0,77 % | Novocure to Report Second Quarter 2026 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,400 | -0,59 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| REVOLUTION MEDICINES | 167,80 | +1,36 % | +422% in einem Jahr: Revolution Medicines nach Bauchspeicheldrüsenkrebs-Durchbruch nicht zu ... | Die Rekordfahrt bei der Aktie von Revolution Medicines hat sich zu Wochenbeginn fortgesetzt. Erstmals in der Börsengeschichte der Biotech-Gesellschaft ist der Börsenwert auf über 40 Milliarden Dollar... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,150 | -6,53 % | ROCKET PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| PALISADE BIO | 2,100 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,899 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from... ► Artikel lesen | |
| OMEROS | 8,400 | +3,45 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,301 | +2,93 % | Outlook Therapeutics, Inc. - 8-K, Current Report |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,331 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.